HomePress ReleasesMilliporeSigma Expands BioReliance® Viral Clearance Offering in Singapore, Saving Customers Time

MilliporeSigma Expands BioReliance® Viral Clearance Offering in Singapore, Saving Customers Time

News Release

  • Allows customers to continue developing lifesaving medicines amid Covid-19 pandemic
  • Customers can view the lab studies “live” with MilliporeSigma scientists

MilliporeSigma today announced an expansion of its Singapore biosafety testing laboratory services. These services allow customers to conduct viral clearance studies that ensure the safety and quality of their biological drugs during the clinical development process.

“With Covid-19 travel restricted between many APAC countries, this expansion allows our customers to continue developing lifesaving medicines without having to travel to our BioReliance® laboratory in Singapore,” said Chris Ross, interim sector head of the Life Science business of MilliporeSigma.

Viral capacity at MilliporeSigma’s Singapore lab has increased by 50 percent to meet demand from biopharmaceutical and cell and gene therapy developers and manufacturers in Asia Pacific. MilliporeSigma’s BioReliance® technical team performs viral capacity studies that adhere to the customer’s protocol using technology and process enhancements that allow the customer to have a similar experience remotely via secure, “live” feed video. Customers do not need to travel away from their home labs, and can watch experiments and receive real-time updates as their process runs. The complete viral clearance services offered by MilliporeSigma scientists include inactivation, filtration and chromatography, all conducted in a Good Laboratory Practice environment. All services are supported by project managers fluent in Chinese, Japanese and Korean and help ensure the safe release of leading medicines to patients around the world.

“This expansion is especially timely, as it will facilitate faster and easier testing for biopharmaceutical companies in the region amid the ongoing Covid-19 pandemic,” said Ms. Goh Wan Yee, senior vice president, Healthcare, Singapore Economic Development Board. “In the long term, companies such as MilliporeSigma contribute significantly to building a holistic supporting ecosystem which will enhance the biopharmaceutical industry.”

Singapore is a leading global science and technology research and development hub committed to growing the biomedical science sector, which has made the life science industry a key economic driver. Demand for viral clearance services has been increasing since the inauguration of MilliporeSigma’s biosafety lab in Singapore in 2018. Travel restrictions related to the Covid-19 pandemic have accelerated the implementation of complete clearance services in the Singapore labs to support biologics customers in Asia. The complete viral clearance service is available in Singapore now, with the increased capacity coming online by April 2021.

MilliporeSigma supports scientists around the world in efforts to accelerate development of treatments for and vaccines against Covid-19 by supplying materials, solutions and bioprocessing manufacturing platforms from its life science business. These offerings support more than 35 testing solutions, among them eight of the top 10 In-Vitro Diagnostic market leaders; more than 50 different vaccine candidates; and more than 20  monoclonal antibodies, plasma products and antivirals.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. 

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.